世界の肺がん診断・治療市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV12547)
◆英語タイトル:Global Lung Cancer Diagnosis and Therapeutics Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV12547
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:128
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは肺がん診断・治療の世界市場について調査・分析した資料です。種類別(非小細胞肺がん、小細胞肺がん)の市場規模、用途別(病院、がん研究センター)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別肺がん診断・治療の競争状況、市場シェア
・世界の肺がん診断・治療市場:種類別市場規模 2015年-2020年(非小細胞肺がん、小細胞肺がん)
・世界の肺がん診断・治療市場:種類別市場規模予測 2021年-2026年(非小細胞肺がん、小細胞肺がん)
・世界の肺がん診断・治療市場:用途別市場規模 2015年-2020年(病院、がん研究センター)
・世界の肺がん診断・治療市場:用途別市場規模予測 2021年-2026年(病院、がん研究センター)
・北米の肺がん診断・治療市場分析:米国、カナダ
・ヨーロッパの肺がん診断・治療市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの肺がん診断・治療市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の肺がん診断・治療市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの肺がん診断・治療市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):AstraZeneca、Eli Lilly、Sanofi、ArQule、Daiichi Sankyo、Celgene、Merck、Pfizer、Boehringer Ingelheim、Roche、Genentech、GSK、Pharmacyclics、Novartis、Bayer、Bristol-Myers Squibb、Eisai、AbbVie
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung.
Robust healthcare expenditure within the developed countries, increasing pollution, government initiatives for lung cancer, and rising cases of smoking are some of the major factors that fuel the growth of the market.

Market Analysis and Insights: Global Lung Cancer Diagnosis and Therapeutics Market
The global Lung Cancer Diagnosis and Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Lung Cancer Diagnosis and Therapeutics Scope and Market Size
Lung Cancer Diagnosis and Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Lung Cancer Diagnosis and Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
AstraZeneca
Eli Lilly
Sanofi
ArQule
Daiichi Sankyo
Celgene
Merck
Pfizer
Boehringer Ingelheim
Roche
Genentech
GSK
Pharmacyclics
Novartis
Bayer
Bristol-Myers Squibb
Eisai
AbbVie

Market segment by Type, the product can be split into
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Market segment by Application, split into
Hospitals
Cancer Research Centers

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Lung Cancer Diagnosis and Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Lung Cancer Diagnosis and Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Non-Small Cell Lung Cancer
1.4.3 Small Cell Lung Cancer
1.5 Market by Application
1.5.1 Global Lung Cancer Diagnosis and Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Research Centers
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Lung Cancer Diagnosis and Therapeutics Market Perspective (2015-2026)
2.2 Global Lung Cancer Diagnosis and Therapeutics Growth Trends by Regions
2.2.1 Lung Cancer Diagnosis and Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Lung Cancer Diagnosis and Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Lung Cancer Diagnosis and Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Lung Cancer Diagnosis and Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Lung Cancer Diagnosis and Therapeutics Players by Market Size
3.1.1 Global Top Lung Cancer Diagnosis and Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Lung Cancer Diagnosis and Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Lung Cancer Diagnosis and Therapeutics Market Concentration Ratio
3.2.1 Global Lung Cancer Diagnosis and Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Lung Cancer Diagnosis and Therapeutics Revenue in 2019
3.3 Lung Cancer Diagnosis and Therapeutics Key Players Head office and Area Served
3.4 Key Players Lung Cancer Diagnosis and Therapeutics Product Solution and Service
3.5 Date of Enter into Lung Cancer Diagnosis and Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Lung Cancer Diagnosis and Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)
5.2 Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
6.2 Lung Cancer Diagnosis and Therapeutics Key Players in North America (2019-2020)
6.3 North America Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
6.4 North America Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
7.2 Lung Cancer Diagnosis and Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
7.4 Europe Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
8.2 Lung Cancer Diagnosis and Therapeutics Key Players in China (2019-2020)
8.3 China Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
8.4 China Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
9.2 Lung Cancer Diagnosis and Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
9.4 Japan Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
10.2 Lung Cancer Diagnosis and Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
11.2 Lung Cancer Diagnosis and Therapeutics Key Players in India (2019-2020)
11.3 India Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
11.4 India Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
12.2 Lung Cancer Diagnosis and Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 AstraZeneca
13.1.1 AstraZeneca Company Details
13.1.2 AstraZeneca Business Overview
13.1.3 AstraZeneca Lung Cancer Diagnosis and Therapeutics Introduction
13.1.4 AstraZeneca Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020))
13.1.5 AstraZeneca Recent Development
13.2 Eli Lilly
13.2.1 Eli Lilly Company Details
13.2.2 Eli Lilly Business Overview
13.2.3 Eli Lilly Lung Cancer Diagnosis and Therapeutics Introduction
13.2.4 Eli Lilly Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.2.5 Eli Lilly Recent Development
13.3 Sanofi
13.3.1 Sanofi Company Details
13.3.2 Sanofi Business Overview
13.3.3 Sanofi Lung Cancer Diagnosis and Therapeutics Introduction
13.3.4 Sanofi Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.3.5 Sanofi Recent Development
13.4 ArQule
13.4.1 ArQule Company Details
13.4.2 ArQule Business Overview
13.4.3 ArQule Lung Cancer Diagnosis and Therapeutics Introduction
13.4.4 ArQule Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.4.5 ArQule Recent Development
13.5 Daiichi Sankyo
13.5.1 Daiichi Sankyo Company Details
13.5.2 Daiichi Sankyo Business Overview
13.5.3 Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Introduction
13.5.4 Daiichi Sankyo Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.5.5 Daiichi Sankyo Recent Development
13.6 Celgene
13.6.1 Celgene Company Details
13.6.2 Celgene Business Overview
13.6.3 Celgene Lung Cancer Diagnosis and Therapeutics Introduction
13.6.4 Celgene Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.6.5 Celgene Recent Development
13.7 Merck
13.7.1 Merck Company Details
13.7.2 Merck Business Overview
13.7.3 Merck Lung Cancer Diagnosis and Therapeutics Introduction
13.7.4 Merck Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.7.5 Merck Recent Development
13.8 Pfizer
13.8.1 Pfizer Company Details
13.8.2 Pfizer Business Overview
13.8.3 Pfizer Lung Cancer Diagnosis and Therapeutics Introduction
13.8.4 Pfizer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.8.5 Pfizer Recent Development
13.9 Boehringer Ingelheim
13.9.1 Boehringer Ingelheim Company Details
13.9.2 Boehringer Ingelheim Business Overview
13.9.3 Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Introduction
13.9.4 Boehringer Ingelheim Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.9.5 Boehringer Ingelheim Recent Development
13.10 Roche
13.10.1 Roche Company Details
13.10.2 Roche Business Overview
13.10.3 Roche Lung Cancer Diagnosis and Therapeutics Introduction
13.10.4 Roche Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.10.5 Roche Recent Development
13.11 Genentech
10.11.1 Genentech Company Details
10.11.2 Genentech Business Overview
10.11.3 Genentech Lung Cancer Diagnosis and Therapeutics Introduction
10.11.4 Genentech Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.11.5 Genentech Recent Development
13.12 GSK
10.12.1 GSK Company Details
10.12.2 GSK Business Overview
10.12.3 GSK Lung Cancer Diagnosis and Therapeutics Introduction
10.12.4 GSK Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.12.5 GSK Recent Development
13.13 Pharmacyclics
10.13.1 Pharmacyclics Company Details
10.13.2 Pharmacyclics Business Overview
10.13.3 Pharmacyclics Lung Cancer Diagnosis and Therapeutics Introduction
10.13.4 Pharmacyclics Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.13.5 Pharmacyclics Recent Development
13.14 Novartis
10.14.1 Novartis Company Details
10.14.2 Novartis Business Overview
10.14.3 Novartis Lung Cancer Diagnosis and Therapeutics Introduction
10.14.4 Novartis Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.14.5 Novartis Recent Development
13.15 Bayer
10.15.1 Bayer Company Details
10.15.2 Bayer Business Overview
10.15.3 Bayer Lung Cancer Diagnosis and Therapeutics Introduction
10.15.4 Bayer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.15.5 Bayer Recent Development
13.16 Bristol-Myers Squibb
10.16.1 Bristol-Myers Squibb Company Details
10.16.2 Bristol-Myers Squibb Business Overview
10.16.3 Bristol-Myers Squibb Lung Cancer Diagnosis and Therapeutics Introduction
10.16.4 Bristol-Myers Squibb Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.16.5 Bristol-Myers Squibb Recent Development
13.17 Eisai
10.17.1 Eisai Company Details
10.17.2 Eisai Business Overview
10.17.3 Eisai Lung Cancer Diagnosis and Therapeutics Introduction
10.17.4 Eisai Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.17.5 Eisai Recent Development
13.18 AbbVie
10.18.1 AbbVie Company Details
10.18.2 AbbVie Business Overview
10.18.3 AbbVie Lung Cancer Diagnosis and Therapeutics Introduction
10.18.4 AbbVie Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.18.5 AbbVie Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

AstraZeneca、Eli Lilly、Sanofi、ArQule、Daiichi Sankyo、Celgene、Merck、Pfizer、Boehringer Ingelheim、Roche、Genentech、GSK、Pharmacyclics、Novartis、Bayer、Bristol-Myers Squibb、Eisai、AbbVie

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の肺がん診断・治療市場2026:インサイト・予測(Global Lung Cancer Diagnosis and Therapeutics Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。